Printer Friendly

PERSEPTIVE BIOSYSTEMS NAMES ALAIN MASSOT SENIOR VICE PRESIDENT, INTERNATIONAL

 CAMBRIDGE, Mass., April 15 /PRNewswire/ -- PerSeptive Biosystems, Inc. (NASDAQ: PBIO) announced today that it has named Alain Massot as senior vice president, international. A 21-year veteran of Millipore Corporation, Massot was most recently corporate vice president for marketing. Prior to that position, Massot was the president of Millipore's Milligen-Biosearch Division, president of Millipore's Analytical (membrane) division and he held various other positions in the worldwide marketing and sales of Millipore's membrane products, including seven years as managing director of Millipore S.A. in Paris.
 Massot will be responsible for all of PerSeptive's international business operations, including its recently-formed subsidiary, PerSeptive Biosystems Gmbh in Freiburg, Germany, and its Japanese subsidiary in formation. He will also coordinate the activities of PerSeptive's network of international distributors.
 "In Alain Massot and John Curling (former president of Pharmacia's Process Division), we now have a team that has 45 years combined experience in the marketing, technical support and sales of the leading bioseparations products internationally. We are now poised to bring to the international markets the productivity gains that our U.S. customer base has begun to experience with the use of our products," noted Noubar B. Afeyan, Ph.D., president and CEO of PerSeptive Biosystems. Afeyan continued, "Alain will build on the groundbreaking work already initiated by John Curling, our vice president of International Business Development, who will now focus full-time on new business development and our emerging process business."
 Curling added, "Alain Massot's decision to join our company is another significant endorsement of our breakthrough separations technologies. We are delighted to have his unparalleled experience and knowledge to support our international marketing, technical support and sales programs."
 Massot received his graduate degree at the E.N.S.C.P. (Higher School of Chemical Engineering) at the Sorbonne in Paris, France.
 PerSeptive Biosystems designs, manufactures and markets proprietary products and systems for the purification and analysis of biomolecules. These bioseparations products are designed to reduce significantly the time and cost required for the development and manufacture of biopharmaceuticals. The company's current and planned products for the purification and analysis of biomolecules are based on three interrelated core technologies: Perfusion Chromatography(R), ImmunoDetection(tm) and Rational Surface Design(tm).
 -0- 4/15/93
 /CONTACT: Robert A. Fein, vice president and chief financial officer of PerSeptive Biosystems, Inc., 617-621-1787, or Pam Haslam of Feinstein Partners Inc., 617-577-8110 for PerSeptive Biosystems/
 (PBIO)


CO: PerSeptive Biosystems Inc. ST: Massachusetts IN: MTC SU: PER

TM -- NE002 -- 6106 04/15/93 10:10 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 15, 1993
Words:413
Previous Article:THREE-FIVE SYSTEMS INC. REPORTS RECORD FIRST QUARTER REVENUES AND EARNINGS
Next Article:INTERNATIONAL MUREX TECHNOLOGIES CORPORATION ANNOUNCES 1992 YEAR END AND FOURTH QUARTER FINANCIAL RESULTS
Topics:


Related Articles
PERSEPTIVE BIOSYSTEMS ANNOUNCES THE EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE 375,000 SHARES, COMPLETING ITS INITIAL PUBLIC OFFERING
PERSEPTIVE BIOSYSTEMS SUBMITS DRUG MASTER FILE WITH FDA COVERING POROS CHROMATOGRAPHY MEDIA
PERSEPTIVE BIOSYSTEMS NAMES JOHN CURLING VICE PRESIDENT, INTERNATIONAL BUSINESS DEVELOPMENT
PERSEPTIVE BIOSYSTEMS NAMES HUBERT M. QUINN VICE PRESIDENT, CHEMICAL PRODUCTION
PERSEPTIVE BIOSYSTEMS AND ISIS PHARMACEUTICALS ANNOUNCE THE FORMATION OF PERISIS: A STRATEGIC ALLIANCE FOR OLIGONUCLEOTIDE MANUFACT. TECHNOLOGIES
PERSEPTIVE BIOSYSTEMS ANNOUNCES ALLOWANCE OF PATENT CLAIMS ON PERFUSIVE CHROMATOGRAPHY PARTICLES
PERSEPTIVE BIOSYSTEMS, INC. ANNOUNCES THIRD QUARTER RESULTS
PERSEPTIVE BIOSYSTEMS ANNOUNCES FILING OF REGISTRATION STATEMENT RELATING TO PERSEPTIVE TECHNOLOGIES II CORP.
PERSEPTIVE BIOSYSTEMS ADDS FORMER COO OF DIGITAL EQUIPMENT CORPORATION TO BOARD OF DIRECTORS
PERSEPTIVE BIOSYSTEMS CREATES NEW EXECUTIVE POST

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters